



InformedDNA®

Genetics, Decoded.

Whole Exome Sequencing, Whole Genome Sequencing, and Genome Wide Copy Number Variant Analysis

Policy Number: GT07

Last Review Date: 10/01/2024
Previous Review Date: 04/01/2024

Table of Contents

Scope.....	3
State Biomarker Legislation.....	3
Guideline Coverage Criteria.....	4
General Criteria for Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS).....	4
Phenotype Suspicious for a Genetic Diagnosis.....	4
Fetal Testing.....	5
Whole Exome Reanalysis.....	6
Genome Wide Copy Number Variant Analysis.....	6
Key Terms and Definitions.....	7
CPT® Codes.....	8
References.....	10
CPT Codes.....	10
Whole Exome Sequencing.....	10
Whole Genome Sequencing.....	14
Genome Wide Copy Number Variant Analysis.....	16
Change Summary.....	18

Scope

This evidence-based guideline addresses the diagnostic use of whole genome copy number variant analysis (e.g., chromosomal microarray analysis [CMA] and low-pass whole genome sequencing), whole exome sequencing (WES), and whole genome sequencing (WGS) in the evaluation of rare disease. This guideline also addresses other broad scale profiling, e.g. whole transcriptome analysis and genome mapping.

This guideline's coverage criteria delineate medically necessary clinical scenarios for molecular testing and may include specific situations when testing is considered never medically necessary. In general, molecular testing is considered never medically necessary when evidence demonstrating its ability to improve diagnosis, management, or clinical outcomes is lacking in peer-reviewed literature.

- This guideline does not address the use of WES as a technology for tumor profiling or genome wide copy number variant analysis, e.g., chromosomal microarray analysis, for oncology indications (please refer to the Somatic Tumor Testing guideline).
- This guideline does not address the use of whole genome copy number variant analysis, e.g., chromosomal microarray analysis, for fetal indications (please refer to the Molecular Testing for Infertility and Pregnancy Loss or the Preimplantation Testing, Prenatal Cell-Free DNA Screening, and Prenatal Diagnosis guidelines).

State Biomarker Legislation

Medical necessity determinations must also take into consideration controlling state coverage mandates that may supersede these guidelines when applicable. When state biomarker legislation requirements impact coverage decisions, this guideline will initially be applied to determine if criteria are met for approval. If an approval cannot be granted based on the criteria in this guideline, some or all of the following sources will be reviewed, as defined by applicable state legislation, to determine if test coverage is supported in a manner that is consistent with the state biomarker legislation requirements:

- Medicare National Coverage Determinations (NCDs)
- Medicare Local Coverage Determinations (LCDs)
- U.S. Food and Drug Administration (FDA) approved or cleared tests
- Tests indicated for an FDA-approved drug
- Nationally recognized clinical practice guidelines
- Consensus statements

Guideline Coverage Criteria

General Criteria for Whole Exome Sequencing (WES) or Whole Genome Sequencing (WGS)

WES/WGS is medically necessary when all of the following criteria are met:

- Results will directly impact clinical decision-making and/or clinical outcome
- No other causative circumstances (e.g., environmental exposures, injury, prematurity, infection) can explain symptoms
- Clinical presentation does not fit a well-described syndrome for which single-gene or targeted panel testing is available
- The differential diagnosis list and/or phenotype warrant testing of multiple genes, and at least one of the following:
 - WES/WGS is more practical than the separate single gene tests or panels that would be recommended based on the differential diagnosis
 - WES/WGS results may preclude the need for multiple and/or invasive procedures, follow-up, or screening (“diagnostic odyssey”) that would be recommended in the absence of testing

Phenotype Suspicious for a Genetic Diagnosis

WES (81415 with or without 81416) or WGS (81425 with or without 81426) are medically necessary when testing is ordered after an individual has been evaluated by a board-certified medical geneticist or other board-certified specialist physician with specific expertise in the conditions being tested for and relevant genes, general criteria for testing above are met, AND any of the following:

- Individual with multiple major structural or functional congenital anomalies affecting unrelated organ systems (including major metabolic disorders), **OR**
- Individual with one major structural or functional congenital anomaly and two or more minor structural anomalies, **OR**
- Individual with one major structural congenital anomaly and a family history strongly implicating a genetic etiology **OR**
- Individual with known or suspected developmental and epileptic encephalopathy (onset before three years of age) for which likely non-genetic causes of epilepsy (e.g., environmental exposures; brain injury secondary to complications of extreme prematurity, infection, trauma) have been excluded, **OR**
- Individual diagnosed with global developmental delay* following formal assessment by a developmental pediatrician or neurologist, **OR**
- Individual diagnosed with moderate/severe/profound intellectual disability** following formal assessment by a developmental pediatrician or neurologist, **OR**
- Individual with confirmed congenital bilateral sensorineural hearing loss of unknown etiology

*Global developmental delay is defined as significant delay in younger children, <5 years of age, in at least two of the major developmental domains: gross or fine motor; speech and language; cognition; social and personal development; and activities of daily living.

**Moderate/severe/profound intellectual disability as defined by DSM-5 criteria diagnosed by 18 years of age.

Fetal Testing

WES (81415 with or without 81416) is medically necessary when general criteria for testing above are met and all of the following criteria:

- Standard diagnostic genetic testing (chromosomal microarray analysis [CMA] and/or karyotype) of the fetus has been performed and is uninformative **AND**
- Testing is ordered in conjunction with a board-certified medical geneticist or genetic counselor **AND**
- Testing is performed on direct amniotic fluid/chorionic villi, cultured cells from amniotic fluid/chorionic villi, or DNA extracted from fetal blood or tissue **AND**
- At least one of the following is present:
 - Multiple fetal structural anomalies affecting unrelated organ systems
 - Fetal hydrops of unknown etiology
 - A fetal structural anomaly affecting a single organ system (please note exclusions below)
 - Isolated anomalies excluded from coverage:
 - Isolated increased nuchal translucency
 - Isolated talipes (clubfeet)
 - Isolated neural tube defect
 - Isolated cleft lip and/or palate
 - Isolated congenital diaphragmatic hernia

Fetal WES is not medically necessary for any of the following indications:

- Healthy pregnancies
- Indications other than fetal structural anomalies
- Ultrasound soft markers of aneuploidy (e.g., choroid plexus cysts, echogenic bowel, intracardiac echogenic focus)

Fetal testing with whole genome sequencing is not medically necessary.

WES/WGS is not medically necessary in the following scenarios:

- Testing using cell-free DNA
- Preimplantation testing of an embryo
- Genetic carrier screening
- Elective genomic testing (WES/WGS)

- Oncology indications
 - Isolated mild intellectual disability
 - Isolated autism spectrum disorder
 - Whole genome sequencing of the transcriptome (RNA sequencing)
 - Genome mapping
-

Whole Exome Reanalysis

Reanalysis of previously obtained uninformative whole exome sequence (81417) is medically necessary when any of the following criteria is met:

- There has been onset of additional symptoms that broadens the phenotype assessed during the original exome evaluation
 - There has been the birth or diagnosis of a similarly affected first-degree relative that has expanded the clinical picture
 - New scientific knowledge suggests a previously unknown link between the patient's findings and specific genes/pathogenic or likely pathogenic variants AND at least 18 months have passed since the last analysis
-

Genome Wide Copy Number Variant Analysis

Genome wide copy number variant analysis (81228, 81229, 81349), using chromosomal microarray analysis or low-pass whole genome sequencing, is medically necessary in the following clinical scenarios.

- Biological parent of a fetus/child with an equivocal or a pathogenic/likely pathogenic copy number variant (CNV) result
- Individual with non-syndromic autism spectrum disorder
- Individual with non-syndromic global developmental delay or intellectual disability*
- Individual with one major anomaly and suspicion for a syndrome caused by a copy number variant, e.g. 22q11.2 deletion syndrome*
- Individual with multiple major structural or functional congenital anomalies affecting unrelated organ systems (including major metabolic disorders)*
- Individual with known or suspected developmental and epileptic encephalopathy (onset before three years of age) for which likely non-genetic causes of epilepsy (e.g. environmental exposures; brain injury secondary to complications of extreme prematurity, infection, trauma) have been excluded*

* *Copy number variant analysis is intended for use in the detection of chromosomal duplications and deletions only and is therefore indicated when the possibility of microdeletion or microduplication syndromes/conditions are suspected. It cannot detect other common variant types (e.g., sequence variants). If sequence variants are high on*

the differential diagnosis, please see the criteria above for whole exome and whole genome sequencing.

Key Terms and Definitions

Aneuploidy is characterized by an extra or missing chromosome, as seen in conditions such as Down syndrome (trisomy 21), trisomy 13, or trisomy 18.

Cell-free DNA refers to fragments of DNA that are released from damaged or dying cells and can be identified in bodily fluids like the blood.

Chromosomes carry genetic material known as DNA; humans typically have 23 pairs of chromosomes.

Chromosomal microarray analysis is a genetic test that analyzes the entire genome for small deletions or duplications, known as copy number variants, in the DNA.

Congenital anomaly refers to a structural or functional abnormality present in a baby at the time of birth which may result from genetic factors, environmental exposures during pregnancy, or a combination of both. Structural congenital anomalies involve physical malformations of body parts or organs. Functional congenital anomalies refer to an abnormality in the normal functioning of a specific organ or system and do not necessarily involve visible structural changes.

Copy number variants are small deletions or duplications in the DNA.

Deoxyribonucleic acid (DNA) is a molecule that contains the genetic instructions for all living organisms and plays a crucial role in the development and susceptibility to diseases.

Exome refers to all of the protein-coding regions in the genome; although it includes only 1-2% of the entire genome, it contains most disease-causing genes.

First-degree relative refers to a biological parent, sibling, or child.

Genes are segments of DNA that contain the instructions for specific traits, characteristics, or functions within an organism.

Genetic (molecular) testing examines a person's DNA or RNA to identify variations that can aid in the diagnosis of disease and/or provide valuable information about a person's risk of developing certain diseases.

Genome refers to an individual's entire set of genetic material (DNA).

Genome mapping involves identifying and sequencing all the genes, non-coding regions, and repetitive sequences that make up an individual's genetic material.

Genotype is the genetic makeup of an individual.

Low-pass whole genome sequencing is a cost-effective and efficient method of whole genome sequencing that involves using a lower coverage depth (the number of times each base pair in the genome is read during sequencing) compared to traditional whole genome sequencing.

Microdeletions refer to the loss of a small segment of DNA from one of the chromosomes.

Microduplications refer to the gain of a small segment of DNA from one of the chromosomes.

Non-syndromic refers to a medical condition or disorder that occurs without other associated clinical features or symptoms commonly seen in a specific group of disorders known as syndromes.

Pathogenic/likely pathogenic variant(s) are specific genetic changes that are known or highly likely to cause a particular genetic disorder, which can aid in diagnosis and/or guide treatment and management strategies.

Pharmacogenomics is a type of precision medicine that studies the influence of an individual's genotype on their body's response to medications.

Phenotype refers to the observable characteristics or features of a genetic disorder.

Preimplantation genetic testing (PGT) is a genetic test used to screen embryos created during in vitro fertilization (IVF) for specific genetic disorders or chromosomal abnormalities.

Sequence variant, also known as a genetic variant, refers to a specific change or alteration in the DNA

sequence when compared to a reference or normal sequence, which can have various effects on an individual's phenotype or health.

Whole exome sequencing (WES) is a technology that involves sequencing the entire exome.

Whole genome sequencing (WGS) is a technology that involves sequencing the entire genome.

Whole transcriptome analysis, also known as RNA sequencing, is a technology that analyzes the complete set of RNA molecules produced by a cell or organism.

CPT[®] Codes

Medical necessity review of claims may include evaluation of the submitted codes. Laboratories must accurately represent their services using the most applicable and specific CPT code(s). Tier 1 molecular pathology procedure codes or Proprietary Laboratory Analyses (PLA) codes should be used when available for the specific test. Tier 2 molecular pathology procedure codes should only be used if the American Medical Association (AMA) has specifically assigned the performed test to such a code. Genomic sequencing procedures (GSP) codes (e.g., CPT codes 81410-81471) were developed by the AMA to represent multi-gene panels utilizing DNA or RNA analysis for specific clinical scenarios (e.g., carrier screening, tumor testing, etc.) and should be utilized when applicable.

Coding guidelines can be found in the AMA's CPT manual as well as the Centers for Medicare and Medicaid Services (CMS) National Correct Coding Initiative (NCCI) policy manuals. NCCI General Correct Coding Policy states that procedures should be reported with the most comprehensive CPT code describing the services performed and that the services described by a CPT code cannot be unbundled into multiple less specific codes. Additionally, GSP codes should be utilized when appropriate for the described test and should not be submitted along with other CPT codes that represent components of the GSP code.

Claims may not be approved if the submitted codes are not the most appropriate for the described procedure (i.e., as accurate and specific as available).

The following code(s) are medically necessary when coverage criteria are met. This list is not all inclusive.

Code	Full Description
81228	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [CGH] microarray analysis
81229	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis
81415	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81416	Exome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator exome (eg, parents, siblings) (List separately in addition to code for primary procedure)
81417	Exome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained

	exome sequence (eg, updated knowledge or unrelated condition/syndrome)
81425	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis
81426	Genome (eg, unexplained constitutional or heritable disorder or syndrome); sequence analysis, each comparator genome (eg, parents, siblings) (List separately in addition to code for primary procedure)
0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities
0212U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband (Do not report 0212U in conjunction with 81425)
0213U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling) (Do not report 0213U in conjunction with 81426)
0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband (Do not report 0214U in conjunction with 81415)
0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent, sibling) (Do not report 0215U in conjunction with 81416)
0265U	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants

The following code(s) are considered never medically necessary. This list is not all inclusive.

Code	Full Description
81427	Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome)
0260U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping
0266U	Unexplained constitutional or other heritable disorders or syndromes, tissue specific gene expression by whole transcriptome and next-generation sequencing, blood, formalin-fixed paraffin embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes
0267U	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing
0454U	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping

References

CPT Codes

AMA CPT® Professional 2024. American Medical Association

NCCI Policy Manual for Medicare Services. Available at:
<https://www.cms.gov/Medicare/Coding/NationalCorrectCodInitEd>. Accessed quarterly.

NCCI Policy Manual for Medicaid Services. Available at:
<https://www.medicaid.gov/medicaid/program-integrity/national-correct-coding-initiative/medicaid-ncci-reference-documents/index.html>

Whole Exome Sequencing

Aarabi M, Sniezek O, Jiang H, et al. Importance of complete phenotyping in prenatal whole exome sequencing. *Hum Genet.* 2018 Feb;137(2):175-181. doi: 10.1007/s00439-017-1860-1. Epub 2018 Feb 1. PMID: 29392406.

Abou Tayoun A, Mason-Suares H. Considerations for whole exome sequencing unique to prenatal care. *Hum Genet.* 2020 Sep;139(9):1149-1159. doi: 10.1007/s00439-019-02085-7. Epub 2019 Nov 7. PMID: 31701237.

ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. *Genet Med.* 2012 Aug;14(8):759-61. doi: 10.1038/gim.2012.74. PubMed PMID: 22863877.

ACMG Board of Directors. Points to consider for informed consent for genome/exome sequencing. *Genet Med.* 2013 Sep;15(9):748-9. doi: 10.1038/gim.2013.94. Epub 2013 Aug 22. PubMed PMID: 23970068.

Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. *Genet Med.* 2018 Nov;20(11):1328-1333. doi: 10.1038/gim.2018.41. Epub 2018 Mar 22. PMID: 29565419.

Amendola LM, Jarvik GP, Leo MC, et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. *Am J Hum Genet.* 2016 Jun 2; 98(6):1067-76. Epub 2016 May 12. Erratum in: *Am J Hum Genet.* 2016 Jul 7;99(1):247. PMID: 27181684; PMCID: PMC4908185.

Anazi S, Maddirevula S, Faqeih E, et al. Clinical genomics expands the morbid genome of intellectual disability and offers a high diagnostic yield. *Mol Psychiatry.* 2017 Apr;22(4):615-624. doi: 10.1038/mp.2016.113. Epub 2016 Jul 19. PMID: 27431290.

Bademci G, Foster J 2nd, Mahdih N, et al. Comprehensive analysis via exome sequencing uncovers genetic etiology in autosomal recessive nonsyndromic deafness in a large multiethnic cohort. *Genet Med.* 2016 Apr;18(4):364-71. doi: 10.1038/gim.2015.89. Epub 2015 Jul 30. Erratum in: *Genet Med.* 2016 Aug;18(8):859. PMID: 26226137; PMCID: PMC4733433.

Baldrige D, Heeley J, Vineyard M, et al. The Exome Clinic and the role of medical genetics expertise in the interpretation of exome sequencing results. *Genet Med.* 2017 Sep;19(9):1040-1048. doi: 10.1038/gim.2016.224. Epub 2017 Mar 2. PMID: 28252636; PMCID: PMC5581723.

Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. *N Engl J Med.* 2014 Jun 19;370(25):2418-25. doi: 10.1056/NEJMra1312543. PMID: 24941179.

Bush LW, Bartoshesky LE, David KL, et al. Pediatric clinical exome/genome sequencing and the engagement process: encouraging active conversation with the older child and adolescent: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2018 Jul;20(7):692-694. doi: 10.1038/gim.2018.36. Epub 2018 Mar 22. PMID: 29565417.

Carter MT, Srour M, Au PB, et al. Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists (CCMG). *J Med Genet*. 2023 Jun;60(6):523-532. doi: 10.1136/jmg-2022-108962. Epub 2023 Feb 23. PMID: 36822643; PMCID: PMC10313961.

Copenheaver D, Juusola J, Vitazka P, et al. P2-49 Whole exome sequencing as a diagnostic tool for cases of fetal demise or termination. Poster Abstracts of the ISPD 19th International Conference on Prenatal Diagnosis and Therapy, Washington, DC, USA, 12–15 July 2015. *Prenat Diagn*, 35, 27–109. doi: 10.1002/pd.4617. PMID: 26108197.

Daum H, Meiner V, Elpeleg O, et al. Fetal exome sequencing: yield and limitations in a single tertiary center. *Ultrasound Obstet Gynecol*. 2018 Jun 26. doi: 10.1002/uog.19168. PMID: 29947050.

Donley G, Hull SC, Berkman BE. Prenatal whole genome sequencing: just because we can, should we? *Hastings Cent Rep*. 2012 Jul-Aug;42(4):28-40. doi:10.1002/hast.50. Epub 2012 Jun 20. PubMed PMID: 22777977.

Downie L, Halliday J, Burt R, et al. Exome sequencing in infants with congenital hearing impairment: a population-based cohort study. *Eur J Hum Genet*. 2020 May;28(5):587-596. doi: 10.1038/s41431-019-0553-8. Epub 2019 Dec 12. Erratum in: *Eur J Hum Genet*. 2020 Nov 9; Erratum in: *Eur J Hum Genet*. 2021 Aug;29(8):1316. PMID: 31827275; PMCID: PMC7171096.

Drury S, Trump N, Boustred C, et al. T-1 Exome sequencing for prenatal diagnosis of abnormalities detected by ultrasound. Poster Abstracts of the ISPD 19th International Conference on Prenatal Diagnosis and Therapy, Washington, DC, USA, 12–15 July 2015. *Prenat Diagn*, 35, 27–109. doi: 10.1002/pd.4617. PMID: 26108197.

Ewans LJ, Minoche AE, Schofield D, et al. Whole exome and genome sequencing in mendelian disorders: a diagnostic and health economic analysis. *Eur J Hum Genet*. 2022 Oct;30(10):1121-1131. doi: 10.1038/s41431-022-01162-2. Epub 2022 Aug 15. PMID: 35970915; PMCID: PMC9553973.

Ewans LJ, Schofield D, Shrestha R, et al. Whole-exome sequencing reanalysis at 12 months boosts diagnosis and is cost-effective when applied early in Mendelian disorders. *Genet Med*. 2018 Mar 29. doi: 10.1038/gim.2018.39. Epub 2018 Mar 29. PMID: 29595814.

Felice V, Abhyankar A, Jobanputra V. Prenatal Diagnosis by Whole Exome Sequencing in Fetuses with Ultrasound Abnormalities. *Methods Mol Biol*. 2019;1885:267-285. doi: 10.1007/978-1-4939-8889-1_18. PubMed PMID: 30506204.

Fu F, Li R, Li Y, et al. Whole exome sequencing as a diagnostic adjunct to clinical testing in fetuses with structural abnormalities. *Ultrasound Obstet Gynecol*. 2018 Apr;51(4):493-502. doi: 10.1002/uog.18915. PMID: 28976722.

Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet Med*. 2013 Jul;15(7):565-74. doi: 10.1038/gim.2013.73. Epub 2013 Jun 20. PubMed PMID: 23788249; PubMed Central PMCID: PMC3727274.

Hiatt SM, Amaral MD, Bowling KM, et al. Systematic reanalysis of genomic data improves quality of variant interpretation. *Clin Genet*. 2018 Jul;94(1):174-178. doi: 10.1111/cge.13259. Epub 2018 May 10. PMID: 29652076; PMCID: PMC5995667.

Howell KB, Eggers S, Dalziel K, et al. A population-based cost-effectiveness study of early genetic testing in severe epilepsies of infancy. *Epilepsia*. 2018 Jun;59(6):1177-1187. doi: 10.1111/epi.14087. Epub 2018 May 11. PMID: 29750358; PMCID: PMC5990455.

International Society for Prenatal Diagnosis; Society for Maternal and Fetal Medicine; Perinatal Quality Foundation. Joint Position Statement from the International Society for Prenatal Diagnosis (ISPD), the Society for Maternal Fetal Medicine (SMFM), and the Perinatal Quality Foundation (PQF) on the use of genome-wide sequencing for fetal diagnosis. *Prenat Diagn*. 2018 Jan;38(1):6-9. doi: 10.1002/pd.5195. PubMed PMID: 29315690.

Jurgens J, Ling H, Hetrick K, et al. Assessment of incidental findings in 232 whole-exome sequences from the Baylor-Hopkins Center for Mendelian Genomics. *Genet Med*. 2015 Jan 8. doi: 10.1038/gim.2014.196. Epub 2015 Jan 8. PMID: 25569433; PMCID: PMC4496331.

Kalia SS, Adelman K, Bale SJ, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. *Genet Med.* 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17. Erratum in: *Genet Med.* 2017 Apr;19(4):484. PMID: 27854360.

Korver AM, Smith RJ, Van Camp G, et al. Congenital hearing loss. *Nat Rev Dis Primers.* 2017 Jan 12;3:16094. doi: 10.1038/nrdp.2016.94. PMID: 28079113; PMCID: PMC5675031.

Kurian AW, Hare EE, Mills MA, et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. *J Clin Oncol.* 2014 Jul 1;32(19):2001-9. doi: 10.1200/JCO.2013.53.6607. Epub 2014 Apr 14. PMID: 24733792; PMCID: PMC4067941.

Kurki MI, Saarentaus E, Pietiläinen O, et al. Contribution of rare and common variants to intellectual disability in a sub-isolate of Northern Finland. *Nat Commun.* 2019 Jan 24;10(1):410. doi: 10.1038/s41467-018-08262-y. PMID: 30679432; PMCID: PMC6345990.

Li MM, Tayoun AA, DiStefano M, et al. Clinical evaluation and etiologic diagnosis of hearing loss: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2022 Jul;24(7):1392-1406. doi: 10.1016/j.gim.2022.03.018. Epub 2022 May 10. PMID: 35802133.

Lord J, McMullan DJ, Eberhardt RY, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study. *Lancet.* 2019 Feb 23;393(10173):747-757. doi: 10.1016/S0140-6736(18)31940-8. Epub 2019 Jan 31. PMID: 30712880; PMCID: PMC6386638.

Malinowski J, Miller DT, Demmer L, et al; ACMG Professional Practice and Guidelines Committee. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. *Genet Med.* 2020 Mar 23. doi: 10.1038/s41436-020-0771-z. Epub 2020 Mar 23. PMID: 32203227; PMCID: PMC7222126.

Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Nov;23(11):2029-2037. doi: 10.1038/s41436-021-01242-6. Epub 2021 Jul 1. PMID: 34211152.

Miller DT, Lee K, Gordon AS, et al.; ACMG Secondary Findings Working Group. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Aug;23(8):1391-1398. doi: 10.1038/s41436-021-01171-4. Epub 2021 May 20. PMID: 34012069.

Monaghan KG, Leach NT, Pekarek D, et al.; ACMG Professional Practice and Guidelines Committee. The use of fetal exome sequencing in prenatal diagnosis: a point to consider document of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2020 Apr;22(4):675-680. doi: 10.1038/s41436-019-0731-7. Epub 2020 Jan 8. PMID: 31911674.

Murray MF, Giovanni MA, Doyle DL, et al. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Jun;23(6):989-995. doi: 10.1038/s41436-020-01082-w. Epub 2021 Mar 16. PMID: 33727704.

Myers KA, Johnstone DL, Dymant DA. Epilepsy genetics: Current knowledge, applications, and future directions. *Clin Genet.* 2019 Jan;95(1):95-111. doi: 10.1111/cge.13414. Epub 2018 Aug 2. PMID: 29992546.

National Society of Genetic Counselors. Position statement on incidental findings in genetic testing. <https://www.nsgc.org/Policy-Research-and-Publications/Position-Statements/Position-Statements/Post/secondary-and-incidental-findings-in-genetic-testing-1>

Nolan D, Carlson M. Whole Exome Sequencing in Pediatric Neurology Patients: Clinical Implications and Estimated Cost Analysis. *J Child Neurol*. 2016 Jun;31(7):887-94. doi: 10.1177/0883073815627880. Epub 2016 Feb 10. PMID: 26863999.

Ontario Health (Quality). Genome-Wide Sequencing for Unexplained Developmental Disabilities or Multiple Congenital Anomalies: A Health Technology Assessment. *Ont Health Technol Assess Ser*. 2020 Mar 6;20(11):1-178. PMID: 32194879; PMCID: PMC7080457.

Palmer EE, Schofield D, Shrestha R, et al. Integrating exome sequencing into a diagnostic pathway for epileptic encephalopathy: Evidence of clinical utility and cost effectiveness. *Mol Genet Genomic Med*. 2018 Mar;6(2):186-199. doi: 10.1002/mgg3.355. Epub 2018 Jan 4. PMID: 29314763; PMCID: PMC5902395.

Pasipoularides A. the new era of whole-exome sequencing in congenital heart disease: brand-new insights into rare pathogenic variants. *J Thorac Dis*. 2018 Jun; 10(Suppl 17): S1923-S1929. PubMed PMID: 30023082.

Petrovski S, Aggarwal V, Giordano JL, et al. Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study. *Lancet*. 2019 Feb 23;393(10173):758-767. PubMed PMID: 3071287.

Reilly K, Sonner S, McCay N, et al. The incremental yield of prenatal exome sequencing over chromosome microarray for congenital heart abnormalities: A systematic review and meta-analysis. *Prenat Diagn*. 2024 Jun;44(6-7):821-831. doi: 10.1002/pd.6581. Epub 2024 May 6. PMID: 38708840.

Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med*. 2013 May;15(5):399-407. doi: 10.1038/gim.2013.32. Epub 2013 Mar 21. Erratum in: *Genet Med*. 2013 Aug;15(8):669. PMID: 23519317.

Shashi V, McConkie-Rosell A, Rosell B, et al. The utility of the traditional medical genetics diagnostic evaluation in the context of next-generation sequencing for undiagnosed genetic disorders. *Genet Med*. 2014 Feb;16(2):176-82. doi: 10.1038/gim.2013.99. Epub 2013 Aug 29. PubMed PMID: 23928913.

Shashi V, McConkie-Rosell A, Schoch K, et al. Practical considerations in the clinical application of whole-exome sequencing. *Clin Genet*. 2015 Feb 12. doi: 10.1111/cge.12569. Epub 2015 Mar 15. PMID: 25678066.

Sheidley BR, Smith LA, and KL Helbig, et al. Genetics of epilepsy in the era of precision medicine: implications for testing, treatment, and genetic counseling. *Curr Genet Med Rep*. 2018; 6(2): 73-8. <https://doi.org/10.1007/s40142-018-0139-8>.

Srivastava S, Cohen JS, Vernon H, et al. Clinical whole exome sequencing in child neurology practice. *Ann Neurol*. 2014 Oct;76(4):473-83. doi: 10.1002/ana.24251. Epub 2014 Aug 30. PMID: 25131622.

Stark Z, Lunke S, Brett GR, et al. Meeting the challenges of implementing rapid genomic testing in acute pediatric care. *Genet Med*. 2018 Mar 15. doi: 10.1038/gim.2018.37. Epub 2018 Mar 15. PMID: 29543227.

Van den Veyver IB, Chandler N, Wilkins-Haug LE, et al. International Society for Prenatal Diagnosis Updated Position Statement on the use of genome-wide sequencing for prenatal diagnosis. *Prenat Diagn*. 2022 May;42(6):796-803. doi: 10.1002/pd.6157. PMID: 35583085.

van El CG, Cornel MC, Borry P, et al. Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics. *Eur J Hum Genet*. 2013 Jun;21(6):580-4. doi: 10.1038/ejhg.2013.46. PubMed PMID: 23676617; PubMed Central PMCID: PMC3658192.

Vissers LE, van Nimwegen KJ, Schieving JH, et al. A clinical utility study of exome sequencing versus conventional genetic testing in pediatric neurology. *Genet Med*. 2017 Mar 23. doi: 10.1038/gim.2017.1. Epub 2017 Mar 23. PMID: 28333917; PMCID: PMC5589982.

Vora NL, Norton ME. Prenatal exome and genome sequencing for fetal structural abnormalities. *Am J Obstet Gynecol*. 2023 Feb;228(2):140-149. doi: 10.1016/j.ajog.2022.08.040. Epub 2022 Aug 24. PMID: 36027950; PMCID: PMC9877148.

Vrijenhoek T, Middelburg EM, Monroe GR, et al. Whole-exome sequencing in intellectual disability; cost before and after a diagnosis. *Eur J Hum Genet.* 2018 Jun 29. doi: 10.1038/s41431-018-0203-6. Epub 2018 Jun 29. PMID: 29959382; PMCID: PMC6189079.

Winand R, Hens K, Dondorp W, et al. In vitro screening of embryos by whole-genome sequencing: now, in the future or never? *Hum Reprod.* 2014 Apr;29(4):842-51. doi: 10.1093/humrep/deu005. Epub 2014 Feb 2. PMID: 24491297.

Yadava SM, Ashkinadze E. Whole exome sequencing for prenatal diagnosis in cases with fetal anomalies: Criteria to improve diagnostic yield. *J Genet Couns.* 2018 Dec 12. doi: 10.1002/jgc4.1045. Epub 2018 Dec 12. PMID: 30629328.

Yang Y, Muzny DM, Reid JG, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N Engl J Med.* 2013 Oct 17;369(16):1502-11. doi: 10.1056/NEJMoa1306555. Epub 2013 Oct 2. PMID: 24088041; PMCID: PMC4211433.

Yang Y, Muzny DM, Xia F, et al. Molecular findings among patients referred for clinical whole-exome sequencing. *JAMA* 2014; 312:1870–1879. doi: 10.1001/jama.2014.14601. PMID: 25326635; PMCID: PMC4326249.

Yates CL, Monaghan KG, Copenheaver D, et al. Whole-exome sequencing on deceased fetuses with ultrasound anomalies: expanding our knowledge of genetic disease during fetal development. *Genet Med.* 2017 Oct;19(10):1171-1178. doi: 10.1038/gim.2017.31. Epub 2017 Apr 20. PMID: 28425981.

Zawati MH, Parry D, Thorogood A, et al. Reporting results from whole-genome and whole-exome sequencing in clinical practice: a proposal for Canada? *J Med Genet.* 2014 Jan;51(1):68-70. doi: 10.1136/jmedgenet-2013-101934. Epub 2013 Sep 27. PubMed PMID: 24078715.

Zou S, Mei X, Yang W, et al. Whole-exome sequencing identifies rare pathogenic and candidate variants in sporadic Chinese Han deaf patients. *Clin Genet.* 2020 Feb;97(2):352-356. doi: 10.1111/cge.13638. Epub 2019 Sep 10. PMID: 31486067.

Whole Genome Sequencing

Aarabi M, Snizek O, Jiang H, et al. Importance of complete phenotyping in prenatal whole exome sequencing. *Hum Genet.* 2018 Feb;137(2):175-181. doi: 10.1007/s00439-017-1860-1. Epub 2018 Feb 1. PMID: 29392406.

ACMG Board of Directors. Points to consider for informed consent for genome/exome sequencing. *Genet Med.* 2013 Sep;15(9):748-9. doi: 10.1038/gim.2013.94. Epub 2013 Aug 22. PMID: 23970068.

ACMG Board of Directors. Points to consider in the clinical application of genomic sequencing. *Genet Med.* 2012 Aug;14(8):759-61. doi: 10.1038/gim.2012.74. PMID: 22863877.

Alfares A, Aloraini T, Subaie LA, et al. Whole-genome sequencing offers additional but limited clinical utility compared with reanalysis of whole-exome sequencing. *Genet Med.* 2018 Nov;20(11):1328-1333. doi: 10.1038/gim.2018.41. Epub 2018 Mar 22. PMID: 29565419.

Brockman DG, Austin-Tse CA, Pelletier RC, et al. Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. *Genet Med.* 2021 Sep;23(9):1689-1696. doi: 10.1038/s41436-021-01193-y. Epub 2021 May 11. PMID: 33976420; PMCID: PMC8488861.

Ceyhan-Birsoy O, Murry JB, Machini K, et al. Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project. *Am J Hum Genet.* 2019 Jan 3;104(1):76-93. doi: 10.1016/j.ajhg.2018.11.016. PMID: 30609409; PMCID: PMC6323417.

Clark MM, Stark Z, Farnaes L, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. *NPJ Genom Med.* 2018 Jul 9;3:16. doi: 10.1038/s41525-018-0053-8. PMID: 30002876; PMCID: PMC6037748.

- Dimmock DP, Clark MM, Gaughran M, et al. An RCT of Rapid Genomic Sequencing among Seriously Ill Infants Results in High Clinical Utility, Changes in Management, and Low Perceived Harm. *Am J Hum Genet.* 2020 Nov 5;107(5):942-952. doi: 10.1016/j.ajhg.2020.10.003. PMID: 33157007; PMCID: PMC7675004.
- Lantos JD. Ethical and Psychosocial Issues in Whole Genome Sequencing (WGS) for Newborns. *Pediatrics.* 2019 Jan;143(Suppl 1):S1-S5. doi: 10.1542/peds.2018-1099B. PubMed PMID: 30600264.
- Li MM, Tayoun AA, DiStefano M, et al. Clinical evaluation and etiologic diagnosis of hearing loss: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2022 Jul;24(7):1392-1406. doi: 10.1016/j.gim.2022.03.018. Epub 2022 May 10. PMID: 35802133.
- Lindstrand A, Ek M, Kvarnung M, et al. Genome sequencing is a sensitive first-line test to diagnose individuals with intellectual disability. *Genet Med.* 2022 Nov;24(11):2296-2307. doi: 10.1016/j.gim.2022.07.022. Epub 2022 Sep 6. PMID: 36066546.
- Lionel AC, Costain G, Monfared N, et al. Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. *Genet Med.* 2018 Apr;20(4):435-443. doi: 10.1038/gim.2017.119. Epub 2017 Aug 3. PMID: 28771251; PMCID: PMC5895460.
- Malinowski J, Miller DT, Demmer L, et al. Systematic evidence-based review: outcomes from exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability. *Genet Med.* 2020 Jun;22(6):986-1004. doi: 10.1038/s41436-020-0771-z. Epub 2020 Mar 23. PMID: 32203227; PMCID: PMC7222126.
- Manickam K, McClain MR, Demmer LA, et al. Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Nov;23(11):2029-2037. doi: 10.1038/s41436-021-01242-6. Epub 2021 Jul 1. PMID: 34211152.
- Miller DT, Lee K, Gordon AS, et al.; ACMG Secondary Findings Working Group. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Aug;23(8):1391-1398. doi: 10.1038/s41436-021-01171-4. Epub 2021 May 20. PMID: 34012069.
- Monaghan KG, Leach NT, Pekarek D, et al. The use of fetal exome sequencing in prenatal diagnosis: a points to consider document of the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2020 Apr;22(4):675-680. doi: 10.1038/s41436-019-0731-7. Epub 2020 Jan 8. PMID: 31911674.
- Murray MF, Giovanni MA, Doyle DL, et al. DNA-based screening and population health: a points to consider statement for programs and sponsoring organizations from the American College of Medical Genetics and Genomics (ACMG). *Genet Med.* 2021 Jun;23(6):989-995. doi: 10.1038/s41436-020-01082-w. Epub 2021 Mar 16. PMID: 33727704.
- Nurchis MC, Altamura G, Riccardi MT, et al. Whole genome sequencing diagnostic yield for paediatric patients with suspected genetic disorders: systematic review, meta-analysis, and GRADE assessment. *Arch Public Health.* 2023 May 25;81(1):93. doi: 10.1186/s13690-023-01112-4. PMID: 37231492; PMCID: PMC10210272.
- Palmer EE, Sachdev R, Macintosh R, et al. Diagnostic Yield of Whole Genome Sequencing After Nondiagnostic Exome Sequencing or Gene Panel in Developmental and Epileptic Encephalopathies. *Neurology.* 2021 Mar 30;96(13):e1770-e1782. doi: 10.1212/WNL.0000000000011655. Epub 2021 Feb 10. PMID: 33568551.
- Petrikina JE, Cakici JA, Clark MM, et al. The NSIGHT1-randomized controlled trial: rapid whole-genome sequencing for accelerated etiologic diagnosis in critically ill infants. *NPJ Genom Med.* 2018 Feb 9;3:6. doi: 10.1038/s41525-018-0045-8. PMID: 29449963; PMCID: PMC5807510.

Sanford EF, Clark MM, Farnaes L, et al. Rapid Whole Genome Sequencing Has Clinical Utility in Children in the PICU. *Pediatr Crit Care Med*. 2019 Nov;20(11):1007-1020. doi: 10.1097/PCC.0000000000002056. PMID: 31246743; PMCID: PMC6832787.

Shashi V, Schoch K, Spillmann R, et al. A comprehensive iterative approach is highly effective in diagnosing individuals who are exome negative. *Genet Med*. 2019 Jan;21(1):161-172. doi: 10.1038/s41436-018-0044-2. Epub 2018 Jun 15. PMID: 29907797; PMCID: PMC6295275.

Splinter K, Adams DR, Bacino CA, et al. Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. *N Engl J Med*. 2018 Nov 29;379(22):2131-2139. doi: 10.1056/NEJMoa1714458. Epub 2018 Oct 10. PMID: 30304647; PMCID: PMC6481166.

Van den Veyver IB, Chandler N, Wilkins-Haug LE, Wapner RJ, Chitty LS; ISPD Board of Directors. International Society for Prenatal Diagnosis Updated Position Statement on the use of genome-wide sequencing for prenatal diagnosis. *Prenat Diagn*. 2022 May;42(6):796-803. doi: 10.1002/pd.6157. PMID: 35583085.

van der Sanden BPGH, Schobers G, Corominas Galbany J, et al. The performance of genome sequencing as a first-tier test for neurodevelopmental disorders. *Eur J Hum Genet*. 2023 Jan;31(1):81-88. doi: 10.1038/s41431-022-01185-9. Epub 2022 Sep 16. PMID: 36114283; PMCID: PMC9822884.

Vora NL, Norton ME. Prenatal exome and genome sequencing for fetal structural abnormalities. *Am J Obstet Gynecol*. 2023 Feb;228(2):140-149. doi: 10.1016/j.ajog.2022.08.040. Epub 2022 Aug 24. PMID: 36027950; PMCID: PMC9877148.

Wojcik MH, Lemire G, Berger E, et al. Genome Sequencing for Diagnosing Rare Diseases. *N Engl J Med*. 2024 Jun 6;390(21):1985-1997. doi: 10.1056/NEJMoa2314761. PMID: 38838312.

Genome Wide Copy Number Variant Analysis

Abdul-Rahman OA, Hudgins L. The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders. *Genet Med*. 2006 Jan;8(1):50-4. doi: 10.1097/01.gim.0000195304.45116.96. PMID: 16418599.

Allen NM, Conroy J, Shahwan A, et al. Chromosomal microarray in unexplained severe early onset epilepsy – A single centre cohort. *Eur J Paediatr Neurol*. 2015 Jul;19(4):390-4. doi: 10.1016/j.ejpn.2015.03.010. Epub 2015 Apr 10. PMID: 25920948.

Baris HN, Tan WH, Kimonis VE, et al. Diagnostic utility of array-based comparative genomic hybridization in a clinical setting. *Am J Med Genet A*. 2007 Nov 1;143A(21):2523-33. doi: 10.1002/ajmg.a.31988. PMID: 17910064.

Beaudet AL. The utility of chromosomal microarray analysis in developmental and behavioral pediatrics. *Child Dev*. 2013 Jan-Feb;84(1):121-32. doi: 10.1111/cdev.12050. Epub 2013 Jan 11. PMID: 23311723; PMCID: PMC3725967.

Berg AT, Coryell J, Saneto RP, et al. Early-Life Epilepsies and the Emerging Role of Genetic Testing. *JAMA Pediatr*. 2017 Sep 1;171(9):863-871. doi: 10.1001/jamapediatrics.2017.1743. PMID: 28759667; PMCID: PMC5710404.

Chaubey A, Shenoy S, Mathur A, et al. Low-Pass Genome Sequencing: Validation and Diagnostic Utility from 409 Clinical Cases of Low-Pass Genome Sequencing for the Detection of Copy Number Variants to Replace Constitutional Microarray. *J Mol Diagn*. 2020 Jun;22(6):823-840. PMID: 32344035.

Ellison JW, Ravnan JB, Rosenfeld JA, et al. Clinical utility of chromosomal microarray analysis. *Pediatrics*. 2012 Nov;130(5):e1085-95. doi: 10.1542/peds.2012-0568. Epub 2012 Oct 15. PMID: 23071206.

Epilepsy Phenome/Genome Project Epi4K Consortium. Copy number variant analysis from exome data in 349 patients with epileptic encephalopathy. *Ann Neurol*. 2015 Aug;78(2):323-8. doi: 10.1002/ana.24457. Epub 2015 Jul 1. PMID: 26068938; PMCID: PMC4646089.

Gonzales PR, Andersen EF, Brown TR, et al. Interpretation and reporting of large regions of homozygosity and suspected consanguinity/uniparental disomy, 2021 revision: A technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2022 Feb;24(2):255-261. doi: 10.1016/j.gim.2021.10.004. Epub 2021 Dec 3. PMID: 34906464.

Hollenbeck D, Williams CL, Drazba K, et al. Clinical relevance of small copy-number variants in chromosomal microarray clinical testing. *Genet Med*. 2017 Apr;19(4):377-385. doi: 10.1038/gim.2016.132. Epub 2016 Sep 15. PMID: 27632688.

Manning M, Hudgins L; Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. 2010 Nov;12(11):742-5. doi: 10.1097/GIM.0b013e3181f8baad. Erratum in: *Genet Med*. 2020 Dec;22(12):2126. PMID: 20962661; PMCID: PMC3111046.

Manning M, Hudgins L; American College of Medical Genetics and Genomics (ACMG) Professional Practice and Guidelines Committee. Addendum: Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. 2020 Dec;22(12):2126. doi: 10.1038/s41436-020-0848-8. Epub 2020 Jun 8. Erratum for: *Genet Med*. 2010 Nov;12(11):742-5. PMID: 32514088.

Mefford HC, Yendle SC, Hsu C, et al. Rare copy number variants are an important cause of epileptic encephalopathies. *Ann Neurol*. 2011 Dec;70(6):974-85. doi: 10.1002/ana.22645. PMID: 22190369; PMCID: PMC3245646.

Mercimek-Mahmutoglu S, Patel J, Cordeiro D, et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. *Epilepsia*. 2015 May;56(5):707-16. doi: 10.1111/epi.12954. Epub 2015 Mar 25. PMID: 25818041.

Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. 2010 May 14;86(5):749-64. doi: 10.1016/j.ajhg.2010.04.006. PMID: 20466091; PMCID: PMC2869000.

Olson H, Shen Y, Avallone J, et al. Copy number variation plays an important role in clinical epilepsy. *Ann Neurol*. 2014 Jun;75(6):943-58. doi: 10.1002/ana.24178. Epub 2014 Jun 13. PMID: 24811917; PMCID: PMC4487364.

Poduri A. When Should Genetic Testing Be Performed in Epilepsy Patients? *Epilepsy Curr*. 2017 Jan-Feb;17(1):16-22. doi: 10.5698/1535-7511-17.1.16. PMID: 28331464; PMCID: PMC5340549.

Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. *Obstet Gynecol*. 2016 May;127(5):e108-e122. doi: 10.1097/AOG.0000000000001405. PMID: 26938573.

Raca G, Astbury C, Behlmann A, et al; ACMG Laboratory Quality Assurance Committee. Points to consider in the detection of germline structural variants using next-generation sequencing: A statement of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2023 Feb;25(2):100316. PMID: 36507974.

Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. *Genet Med*. 2013 May;15(5):399-407. doi: 10.1038/gim.2013.32. Epub 2013 Mar 21. Erratum in: *Genet Med*. 2013 Aug;15(8):669. PMID: 23519317.

Shao L, Akkari Y, Cooley LD, et al. Chromosomal microarray analysis, including constitutional and neoplastic disease applications, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). *Genet Med*. 2021 Jun 15. doi: 10.1038/s41436-021-01214-w. Epub ahead of print. PMID: 34131312.

Sys M, van den Bogaert A, Roosens B, et al. Can clinical characteristics be criteria to perform chromosomal microarray analysis in children and adolescents with autism spectrum disorders? *Minerva Pediatr.* 2018 Jun;70(3):225-232. doi: 10.23736/S0026-4946.16.04570-9. Epub 2016 Sep 8. PMID: 27607483.

Tumiené B, Maver A, Writzl K, et al. Diagnostic exome sequencing of syndromic epilepsy patients in clinical practice. *Clin Genet.* 2018 May;93(5):1057-1062. doi: 10.1111/cge.13203. Epub 2018 Mar 23. PMID: 29286531.

Wang JC, Ross L, Mahon LW, et al. Regions of homozygosity identified by oligonucleotide SNP arrays: evaluating the incidence and clinical utility. *Eur J Hum Genet.* 2015 May;23(5):663-71. doi: 10.1038/ejhg.2014.153. Epub 2014 Aug 13. PMID: 25118026; PMCID: PMC4402629.

Change Summary

Version	Review Date	Effective Date	Summary of Revisions
Created	CSC: 8/11/2022 PAB: 9/12/2022	November 2022	Not applicable
v1.2023	COOC: 2/15/2023 PAB: 3/16/2023	April 1, 2023	Semi-annual review. No criteria changes.
v2.2023	COOC: 8/16/2023 PAB: 9/25/2023	October 1, 2023	Semi-annual review. No criteria changes.
v1.2024	COOC: 2/14/2024 PAB: 3/25/2024	April 1, 2024	Semi-annual review. No criteria changes. Clarifications were made to the scope and CPT code sections. References were updated.
v2.2024	COOC: 08/19/2024 PAB: 09/20/2024	October 1, 2024	Semi-annual review. Criteria for Fetal WES was expanded to no longer exclude isolated congenital heart defects. References were updated.